Moleculin Reports Q2 Loss, Cash Runway Into Q1 2027, and MIRACLE Trial Milestones
MBRX has more than doubled off its 52-week low of $0.161.
Summary
Moleculin reported Q2 2026 financials with a $7.6M net loss and cash runway into Q1 2027, while confirming MIRACLE trial milestones including a 90-patient enrollment target in September and unblinded data readout in December 2026 to February 2027.
Key Events · Earnings and Guidance · MBRX
-
Q2 2026 Financial Results
Net loss of $7.6M for Q2 2026, with R&D expenses up $1.9M to $5.5M driven by the MIRACLE trial. Cash and equivalents were $7.3M as of June 30, 2026.
-
Cash Runway Extended
Management expects cash on hand plus $9.3M raised after quarter-end to fund operations into Q1 2027, providing near-term liquidity despite going-concern doubts.
-
MIRACLE Trial Milestones
Enrollment completion in Part A expected September 2026, unblinded efficacy readout December 2026 to February 2027, and Part B initiation in 1H 2027.
-
Interim Efficacy Reaffirmed
Positive interim data showed CR rates of 43% and 36% in Annamycin arms vs 12% control, with no cardiotoxicity observed.
Analysis · MBRX · Life Sciences
Moleculin's Q2 results show a $7.6M net loss and $7.3M cash on hand, but the $9.3M raised after quarter-end extends the runway into Q1 2027. The company reiterated positive interim MIRACLE data and set concrete milestones: 90-patient enrollment by September 2026, unblinded readout December 2026 to February 2027, and Part B initiation in 1H 2027. For a micro-cap with going-concern doubts and Nasdaq delisting risk, this update provides critical visibility into both the clinical timeline and the cash runway.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 32.7% of the 1910 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MBRX was trading at $0.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.16 to $17.38. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.